Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jul 16, 2019Aratana Reports Voting Results from 2019 Special Meeting of Stockholders
Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the voting...
-
Jun 11, 2019Commercial availability of NOCITA 10 mL vial size anticipated by fall 2019
Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the U.S. Food...
-
Jun 7, 2019Stockholders Elect All Class III Directors and Approve Proposals
Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the voting...
-
May 8, 2019Continued revenue growth across portfolio of marketed pet therapeutics
Aratana recorded $7.4 million in total revenues for the first quarter of 2019, including $2.5 million in NOCITA net product sales, $1.5 million in ENTYCE net product sales and $3.4 million in licensing and collaboration revenue from Elanco for GALLIPRANT.
-
May 7, 2019
The Company plans on presenting at the Stifel Dental & Veterinary Conference on Wednesday, May 29, 2019 at 8:00 a.m. ET in New York City.
-
Apr 26, 2019Elanco announces formation of commercial team dedicated to veterinary specialty business
The Company announced it has signed an agreement to be acquired by Elanco Animal Health (NYSE: ELAN), its global collaboration partner on GALLIPRANT® (grapiprant tablets). In conjunction with the transaction, Elanco also announced the formation of a commercial team dedicated to the veterinary specialty business. If the proposed agreement is consummated, the Aratana field force would transition into this commercial team.
-
Mar 12, 2019
The Company announced its fourth quarter and full year 2018 financial results and recent business highlights.
-
Feb 13, 2019
The Company plans on attending several upcoming investment conferences, including Bank of America Merrill Lynch Animal Health Summit, Cowen Health Care Conference and Barclays Global Healthcare Conference.
-
Feb 12, 2019
The Company will host a live conference call on Tuesday, March 12, 2019 at 4:30 p.m. ET to discuss financial results from the fourth quarter and full year ended December 31, 2018.
-
Feb 4, 2019
The Company announced the appointment of Rhonda Hellums as Chief Financial Officer and Treasurer of Aratana effective February 1, 2019.
-
Jan 17, 2019
The Company announced today the Board of Directors has appointed Craig Tooman to serve as President and Chief Executive Officer of Aratana, and elected Tooman to the Board of Directors.
-
Nov 1, 2018
Aratana announced its third quarter 2018 financial results, reporting total net revenues of $21.6 million and net income of $8.8 million or $0.19 diluted earnings per share.
-
Oct 22, 2018
Aratana will host a live conference call on Friday, November 2, 2018 at 8:30 a.m. ET to discuss financial results from the third quarter ended September 30, 2018.
-
Aug 29, 2018
The Company plans on presenting at CL King & Associates Best Ideas Conference on Thursday, September 13, 2018 at 1:15 p.m. ET in New York City.
-
Aug 2, 2018
Aratana announced its second quarter 2018 financial results, reporting total net revenues of $4.9 million and a net loss of $6.4 million or $0.14 diluted loss per share.
-
Jul 10, 2018
The Company will host a live conference call on Friday, August 3, 2018 at 8:30 a.m. ET to discuss financial results from the second quarter ended June 30, 2018.
-
Jun 1, 2018
Aratana submitted a supplemental New Animal Drug Application (NADA) for NOCITA® (bupivacaine liposome injectable suspension) with the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) to expand the NOCITA label to include its use in cats as a peripheral nerve block to provide regional post-operative analgesia following onychectomy.
-
May 22, 2018
The Company plans on presenting at Jefferies 2018 Global Healthcare Conference on Tuesday, June 5, 2018 at 4:30 p.m. ET in New York City.
-
May 21, 2018
The Company has appointed Craig Barbarosh and Lowell Robinson to its Board of Directors in connection with a cooperation agreement with Engaged Capital, LLC.
-
May 3, 2018
Aratana announced its first quarter 2018 financial results, reporting total net revenues of $4.0 million and a net loss of $8.5 million or $0.19 diluted loss per share.
-
Apr 12, 2018
The Company will host a live conference call on Friday, May 4, 2018 at 8:30 a.m. ET to discuss financial results from the first quarter ended March 31, 2018.
-
Apr 5, 2018
Aratana confirmed it received a notice of nomination of three director candidates for election to the Company's Board of Directors from Engaged Capital, LLC and certain of its affiliated entities.
-
Mar 13, 2018
Aratana announced its fourth quarter and full year 2017 financial results, reporting total net revenues of $10.4 million and a net loss of $15.6 million or $0.37 diluted loss per share.
-
Mar 2, 2018
The Company plans on attending Cowen and Barclays investment conferences.
-
Mar 1, 2018
Aratana announced it licensed exclusive, worldwide rights to develop and commercialize AT-019 from AskAt Inc. AT-019 is a potent and innovative EP4 receptor antagonist with potential in pain, inflammation and other indications.